• Convergence Pharmaceuticals Ltd., of Cambridge, UK, initiated a Phase II proof-of-concept study of CNV1014802 in pain associated with trigeminal neuralgia (TN). CNV1014802 is a small-molecule, state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel.
Read More
While other drugmakers are spending billions of dollars in pursuit of the next-generation hepatitis C treatment, Okairos AG is on a quest for the holy grail – a preventive hepatitis C virus (HCV) vaccine.
Read More
DUBLIN, Ireland – Innovation Fund Ireland, the Irish government's initiative to bring top-tier international venture capital funds to Ireland, has landed its first biotechnology investor. Sofinnova Ventures is setting up an office in Dublin and is receiving commitments totaling $37.5 million from the country's public purse.
Read More
LONDON – Heptares Therapeutics Ltd. said the starting gun has been fired on a $190 million-plus-royalties deal, after Shire plc decided to take up its option on an A2A antagonist discovered by Heptares.
Read More
LONDON – The discovery of a genetic variant that protects against coronary heart disease has, at long last, allowed scientists to say for certain that an inflammatory pathway plays an important role in causing that condition.
Read More
The Wellcome Trust is setting up a new for-profit investment firm that will have £200 million (US$317 million) on hand to pursue opportunities in health care and in life sciences in the UK and other parts of Europe.
Read More
